University of Minnesota. Driven to Discover.
Partial protection from earlier dengue exposure in the favela population might explain Zika's quick decline there.
Dengue immunity, however, doesn't seem to generally protect against Zika infection, the researchers find.
The findings add to the conundrum that governments face, as the vaccine prevents hospital stays in children who have antibodies to the dengue virus.
The controversial dengue vaccine should not be used until clinicians can confirm prior dengue infection, and such a test is at least 2 years away.
Also, a study shows that receipt of Dengvaxia may alter the accuracy of dengue tests.
Data show that about 4 of 1,000 seronegative patients vaccinated could develop ADE, a serious side effect.
A leading dengue vaccine researcher says the move is not surprising, while Sanofi says antibody-dependent enhancement cannot be the whole story surrounding vaccine performance.
The study highlights ADE, when previous virus exposure enhances disease response.
In the past, the city has experienced outbreaks of dengue, Zika, and chikungunya that were spread by Aedes aegypti mosquitoes.
The antibody protected both adult and fetal mice against Zika infection.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.